Bionano Genomics logo

Bionano GenomicsNASDAQ: BNGO

Profile

Sector:

Healthcare

Country:

United States

IPO:

21 August 2018

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$25.09 M
-98%vs. 3y high
27%vs. sector
-vs. 3y high
-vs. sector
-86%vs. 3y high
28%vs. sector
-99%vs. 3y high
20%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:59:55 GMT
$0.25+$0.02(+6.96%)

Dividend

No data over the past 3 years
$6.07 M$6.45 M
$6.07 M-$44.25 M

Analysts recommendations

Institutional Ownership

BNGO Latest News

Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
seekingalpha.com13 November 2024 Sentiment: NEUTRAL

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Destiny Hance - Ladenburg Thalmann Mark Massaro - BTIG Operator Good day, and welcome to the Bionano Third Quarter 2024 Earnings Conference Call. Today's conference is being recorded.

Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
globenewswire.com31 October 2024 Sentiment: NEUTRAL

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of Stockholders originally held on October 2, 2024 and subsequently adjourned to October 30, 2024 (the “Special Meeting”) because a quorum was not present at the time of the reconvened meeting. Based on preliminary reports as of October 30, 2024, approximately 30.7% of total shares outstanding as of the record date have submitted their votes, whereas 33.3% of total shares outstanding as of the record date are necessary to satisfy the quorum requirements for a meeting.

Bionano Announces Preliminary 3Q 2024 Revenues and Cash
globenewswire.com10 October 2024 Sentiment: NEGATIVE

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue for the third quarter of 2024 to be between $6.5 and $6.8 million, down from prior guidance of between $7.9 and $8.9 million.

Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)
seekingalpha.com13 August 2024 Sentiment: NEUTRAL

Bionano Genomics, Inc. (NASDAQ:BNGO ) Canaccord Genuity 44th Annual Growth Results Conference August 13, 2024 3:30 PM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Kyle Mikson Hi. Welcome to the Canaccord Genuity Global Growth Conference.

Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
zacks.com13 August 2024 Sentiment: POSITIVE

Bionano Genomics (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
globenewswire.com07 August 2024 Sentiment: POSITIVE

Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 nanochannel array flowcells in Q2 2024, which represents a 13% decrease from the number of flowcells sold in Q2 2023 The editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies Conference call today, August 7th, 2024 at 4:30 PM ET SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2024. “We saw positive growth in the OGM installed base this quarter, along with key advancements to our VIA software and the achievement of a significant milestone with the establishment of a Category I CPT code for OGM, which we believe will raise the awareness and utility of OGM,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference
globenewswire.com31 July 2024 Sentiment: POSITIVE

SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024.

3 Sorry Healthcare Stocks to Sell in May While You Still Can
investorplace.com28 May 2024 Sentiment: NEGATIVE

Healthcare stocks often hold significant potential due to the constant demand for medical advancements. However, not all companies in this sector are poised for growth.

3 Contrarian Investments to Make Now for Massive Upside Potential
InvestorPlace25 April 2024 Sentiment: POSITIVE

Many investors are giving up on promising stocks that are unlikely to fail, a trend that has been worsened by excessive concerns about rising interest rates.

Bionano to Present at TD Cowen's 44th Annual Health Care Conference
GlobeNewsWire29 February 2024 Sentiment: POSITIVE

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at TD Cowen's 44th Annual Health Care Conference on March 6, 2024.

  • 1(current)
  • 2

What type of business is Bionano Genomics?

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

What sector is Bionano Genomics in?

Bionano Genomics is in the Healthcare sector

What industry is Bionano Genomics in?

Bionano Genomics is in the Medical Instruments & Supplies industry

What country is Bionano Genomics from?

Bionano Genomics is headquartered in United States

When did Bionano Genomics go public?

Bionano Genomics initial public offering (IPO) was on 21 August 2018

What is Bionano Genomics website?

https://www.bionano.com

Is Bionano Genomics in the S&P 500?

No, Bionano Genomics is not included in the S&P 500 index

Is Bionano Genomics in the NASDAQ 100?

No, Bionano Genomics is not included in the NASDAQ 100 index

Is Bionano Genomics in the Dow Jones?

No, Bionano Genomics is not included in the Dow Jones index

When was Bionano Genomics the previous earnings report?

No data

When does Bionano Genomics earnings report?

The next expected earnings date for Bionano Genomics is 05 March 2025